Abstract: The present invention relates to a novel pharmacological treatment of bacterial infectious diseases in humans. Specifically the invention relates to the use of apramycin of formula (I) or apramycin derivatives to treat bacterial infectious diseases in humans. It is demonstrated that apramycin surprisingly does not have the expected high level of toxicity observed with related aminoglycoside antibiotics but actually is even significantly less toxic than compounds already used in human medicine such as gentamicin.
Abstract: Methods for diagnosing inflammatory and/or cardiovascular diseases by assaying for Fibroblast Activation Protein (FAP) expression in a body fluid is provided as well as therapeutic means based thereon.
Abstract: The present invention provides a method for preventing or repairing damage to a fetal membrane. In one embodiment, the method comprises contacting a fetal membrane with a composition comprising a four-armed catechol-terminated polyethylene glycol (cPEG) and a biocompatible oxidant. In one embodiment, the four-armed cPEG and the biocompatible oxidant are initially contained in separate solutions, and the solutions are mixed to form the composition just prior to or at the same time that the composition contacts the fetal membrane.
Type:
Grant
Filed:
July 29, 2010
Date of Patent:
April 2, 2013
Assignees:
Northwestern University, The University of Zurich
Inventors:
Phillip B. Messersmith, Carrie Brubaker, Corinne Zisch
Abstract: The present invention relates to new rhenium compounds of formula (I) with medical utility, corresponding pharmaceutical compositions as well as medical uses thereof.
Type:
Application
Filed:
March 4, 2011
Publication date:
December 27, 2012
Applicant:
UNIVERSITY OF ZURICH
Inventors:
Fabio Zobi, Roger Alberto, Lukas Kromer
Abstract: The present invention relates to a new polymorphic or crystalline form of Pemetrexed Disodium, processes for its preparation and its use, in particular for the preparation of medicaments.
Type:
Application
Filed:
November 24, 2010
Publication date:
December 27, 2012
Applicants:
UNIVERSITY OF ZURICH, AZAD PHARMACEUTICAL INGREDIENTS AG
Inventors:
Uwe Jens Albrecht, Hannes Helmboldt, Vsevold Valerievich Nikolaev
Abstract: The invention discloses an isolated antibody that selectively binds to the C-terminal part of Abeta and is humanized or fully human. The antibody of the invention is capable of preventing oligomerization of Abeta. Furthermore, a method of diagnosis comprising the steps of: (i) Labelling an antibody; (ii) Administering an effective dose of said antibody intranasally or systemically to a subject; and (iii) Detecting the concentration and/or presence of the labelled antibody in body parts of the subject is disclosed.
Type:
Grant
Filed:
September 15, 2008
Date of Patent:
December 4, 2012
Assignees:
Delenex Therapeutics AG, University of Zurich
Inventors:
Stefan Ewert, Adrian Auf Der Maur, Susann Cattepoel, Roger Nitsch
Abstract: Compounds according to formula (I) are particularly suitable for the treatment and/or prevention of a medical condition involving hypoxic, anoxic and/or inflamed mammalian tissue. Furthermore, the invention relates to the use of said compounds for preparing a medicament and to pharmaceutical preparations comprising such compounds.
Type:
Application
Filed:
July 27, 2010
Publication date:
August 30, 2012
Applicants:
ETH Zurich, University of Zurich
Inventors:
Ludwig K. Limbach, Inge K. Herrmann, Beatrice Beck-Schimmer, Wendelin J. Stark, Martin Urner
Abstract: The present invention relates to the use of glycan-binding polypeptides and glycans as a medicament, in particular for treating and/or preventing helminthic infections or an immune disease. Moreover, the present invention is directed to corresponding pharmaceutical compositions, food products and animal feed comprising isolated glycans and/or glycan-binding polypeptides. In addition, the present invention teaches methods for identifying anti-helminthic carbohydrate-binding polypeptides, for identifying helminthic glycan and gene targets involved in glycan-mediated toxicity, for identifying helminths susceptible to glycan-mediated toxicity, and for identifying anti-helminthic and anti-allergic substances.
Type:
Application
Filed:
October 12, 2010
Publication date:
August 16, 2012
Applicants:
UNIVERSITY OF ZURICH, ETH ZURICH
Inventors:
Markus Kunzler, Martin Walti, Alex Butschi, Markus Aebi, Michael Hengartner
Abstract: The present invention provides a binding molecule which is capable of binding to the human NogoA polypeptide or human NiG with a dissociation constant <1000 nM, a polynucleotide encoding such binding molecule; an expression vector comprising said polynucleotide; an expression system comprising a polynucleotide capable of producing a binding molecule; an isolated host cell which comprises an expression system as defined above; the use of such binding molecule as a pharmaceutical, especially in the treatment of a disease of the peripheral (PNS) and/or central (CNS) nervous system; a pharmaceutical composition comprising said binding molecule; and a method of treatment of a disease of the peripheral (PNS) and/or central (CNS) nervous system.
Type:
Application
Filed:
March 16, 2012
Publication date:
July 5, 2012
Applicants:
University of Zurich, Novartis AG
Inventors:
Carmen Barske, Stefan Frentzel, Anis Khusro Mir, Martin E. Schwab, Alessandra Vitaliti Garami
Abstract: A device and a method for analyzing sound based on a biomorphic design are disclosed. The device comprises a plurality of amplification/filtering stages (S1, . . . , Sn) connected in a series configuration. Each amplification/filtering stage comprises at least one nonlinear amplification module (100a, . . . , 100c), preferably a Hopf amplifier, and at least one filter module (200a? . . . , 200c; 200a?, . . . 200c?) providing high-frequency attenuation.
Type:
Grant
Filed:
May 29, 2006
Date of Patent:
May 8, 2012
Assignee:
University of Zurich
Inventors:
Ruedi Stoop, Albert Kern, Johannes Petrus V. D. Vyver
Abstract: The present invention relates to a method for stabilizing chimeric immunoglobulins or immunoglobulin fragments. Furthermore, the invention also provides a stabilized anti-EGP-2 scFv fragment.
Type:
Grant
Filed:
December 7, 2010
Date of Patent:
March 20, 2012
Assignee:
University of Zurich
Inventors:
Andreas Plückthun, Annemarie Honegger, Jörg Willuda
Abstract: A motion recognizing apparatus and method are provided. According to an aspect, a motion recognizing apparatus may include: an optical sensor configured to sense at least a portion of a subject where a motion occurs and to output one or more events in response thereto; a motion tracing unit configured to trace a motion locus of the portion where the motion occurs based on the one or more outputted events; and a motion pattern determining unit configured to determine a motion pattern of the portion where the motion occurs based on the traced motion locus.
Type:
Application
Filed:
September 9, 2011
Publication date:
March 15, 2012
Applicants:
UNIVERSITY OF ZURICH, SAMSUNG ELECTRONICS CO., LTD.
Inventors:
Jun Haeng LEE, Delbruck TOBI, Hyunsurk RYU, Keun Joo PARK, Chang Woo SHIN
Abstract: The invention relates to therapeutic compounds which are inhibitors of serine proteases, to pharmaceutical compositions thereof and to their use in the treatment of the human or animal body. More specifically, the present invention relates to a method for the treatment of neutropenia comprising the administration to a subject in need thereof of a therapeutically effective amount of a serine protease inhibitor. The invention also comprises prevention of apoptosis of myeloid cells (1) during and after transfection of bone marrow cells performed for gene therapy, (2) during blood stem cell mobilization performed for reconstitution of hematopoiesis and (3) during infusion of cells of the myeloid lineage for reconstitution of hematopoiesis for gene therapy or for treatment of neutropenia by infusion of neutrophils.
Type:
Application
Filed:
March 10, 2010
Publication date:
January 5, 2012
Applicants:
UNIVERSITY OF ZURICH, MED DISCOVERY SA
Inventors:
Adriano Fontana, Mike Recher, Christoph Kundig
Abstract: Provided are human alpha-synuclein-specific autoantibodies as well as fragments, derivatives and variants thereof as well as methods related thereto. Assays, kits, and solid supports related to antibodies specific for ?-synuclein are also disclosed. The antibody, immunoglobulin chain(s), as well as binding fragments, derivatives and variants thereof can be used in pharmaceutical and diagnostic compositions for ?-synuclein targeted immunotherapy and diagnosis, respectively.
Type:
Application
Filed:
December 21, 2009
Publication date:
December 8, 2011
Applicants:
University of Zurich, Panima Pharmaceuticals AG
Inventors:
Andreas Weihofen, Jan Grimm, Roger Nitsch, Christoph Hock
Abstract: Provided is a novel APP (amyloid precursor protein) transgenic non-human animal modeling in vivo the pathophysiological effects and effects on cognitive behavior of early intraneuronal and extracellular brain parenchymal amyloid-? (A?) deposition and cerebral amyloid angiopathy associated with brain microhemorrhages and reduced vasoreactivity and blood flow. Furthermore, methods of screening for therapeutic or diagnostic agents useful in the treatment or diagnosis of Alzheimer's disease, in particular for improving blood flow to the brain are provided as well as the corresponding therapeutic methods.
Type:
Grant
Filed:
June 11, 2008
Date of Patent:
September 20, 2011
Assignee:
The University of Zurich
Inventors:
Jan Grimm, Roger Nitsch, Marlen Knobloch, Uwe Konietzko, Markus Rudin, Thomas Müggler, Felicitas Kranz
Abstract: The present invention relates to polynucleotides encoding adult plant pathogen resistance proteins. Also provided are transgenic plants expressing these polynucleotides to enhance the resistance of the plants to pathogens.
Type:
Application
Filed:
August 25, 2009
Publication date:
September 15, 2011
Applicants:
COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH OR, GRAINS RESEARCH AND DEVELOPMENT CORPORATION, UNIVERSITY OF ZURICH
Inventors:
Evans Lagudah, Wolfgang Spielmeyer, Beat Keller, Simon Krattinger
Abstract: The present invention relates to DNA sequences associated with human memory performance. It also provides methods for (i) screening for diseases and pathological conditions affecting human memory, (ii) identifying agents useful for treatment of diseases and pathological conditions affecting human memory, and (iii) agents and compositions useful for treatment of diseases and pathological conditions affecting human memory.
Type:
Grant
Filed:
January 26, 2007
Date of Patent:
August 9, 2011
Assignees:
Translational Genomics Research Institute, University of Zurich
Inventors:
Andreas Papassotiropoulos, Dietrich Stephan, Dominique J.-F. De Quervain
Abstract: The present description relates generally to methods of using Abeta binding molecules including, for example, antibodies and antibody fragments that recognize Abeta. The description provides methods of promoting neurogenesis, angiogenesis, synaptic activity and/or dendritic arborization using Abeta binding molecules. The description also provides methods of treating various diseases, disorder, injuries and conditions associated with amyloid plaques or the accumulation of Abeta.
Type:
Application
Filed:
July 9, 2009
Publication date:
July 28, 2011
Applicant:
University of Zurich
Inventors:
Roger Nitsch, Olle Lindvall, Barbara Biscaro, Christine Ekdahl
Abstract: The present invention relates to the use of live mycobacterium of the M. tuberculosis complex for preparing a medicament, wherein the function of the zmp1-gene is inactivated, pharmaceutical compositions prepared from such mycobacteria as well as a method for the treatment and/or prophylaxis of a disease or medical condition using said pharmaceutical composition.
Abstract: A composition for coating comprising at least one compound of formula I and optionally at least one compound of formula II RaSi(R1)n(X1)3-n??I RbSi(R2)m(X2)3-m??II wherein Ra is a straight-chain or branched C(1-24) alkyl group, Rb is an aromatic group, such as an optionally substituted carbocyclic and heterocyclic group comprising five-, six- or ten-membered ring systems, which is linked by a single covalent bond or a spacer unit, such as a straight-chain or branched alkyl residue having 1 to 8 carbon atoms, to the Si-atom, R1 and R2 are independently of each other a lower alkyl group, such as a straight chain and branched hydrocarbon radical having 1 to 6 carbon atoms, X1 and X2 are independently of each other a hydrolysable group, such as a halogen or an alkoxy group and n, m are independently of each other 0 or 1, with the proviso that if n and m are independently of each other 0 or 1, X may represent the same or different groups.
Type:
Application
Filed:
January 4, 2011
Publication date:
July 7, 2011
Applicant:
UNIVERSITY OF ZURICH
Inventors:
Jan Zimmermann, Stefan Seeger, Georg Artus, Stefan Jung